-
Plenary III: Secukinumab shows positive results in children with active enthesitis-related arthritis, juvenile psoriatic arthritis
Investigators presented findings from six significant studies, including the JUNIPERA trial, during Plenary III on Monday, Nov. 8.
-
Researchers working to expand role of microbiome in rheumatic diseases
Yasmine Belkaid, PhD, Renuka Nayak, MD, PhD, and Jose U. Scher, MD, discussed a growing body of research designed to harness the microbiota communities that live on our exposed surfaces, from the gut to the skin and eyes.
-
VEXAS syndrome illustrates need for new approach to define complex diseases
Dan Kastner, MD, PhD, described the unique, genotype-first strategy that researchers used to identify and define VEXAS syndrome, a complex rheumatic disease that had not been defined by conventional research approaches.
-
New ACR leadership confirmed at 2021 Business Meeting
Kenneth G. Saag, MD, MSc, became the 85th ACR President on Tuesday, Nov. 9, at the annual ACR Business Meeting. The Board of Directors was also confirmed.
-
Debriefs and Poster Tours extend live programming into February
Beginning December 10, the ACR Convergence virtual platform will be updated nearly every Friday with additional live learning opportunities.
-
Phase 2 AMP data provide insight into molecular landscape of lupus
Researchers from the Accelerating Medicines Partnership SLE Consortium reported phase 2 results during a Sunday morning session.
-
Plenary II: Results from six highly anticipated studies reported
During Sunday morning’s Plenary II session, researchers reported results from the VITAL trial, ORAL Surveillance, and STOP-JIA, among others.
-
Gluck lecturer discusses emerging therapies targeting the role of bone in OA
In Sunday’s Oscar S. Gluck, MD Memorial Lecture, Marc Hochberg, MD, MPH, described research into the pathogenesis and progression of OA that has helped identify new targets for therapeutic intervention.
-
ARP lecturer describes link between employment, poverty, and rheumatic diseases
Musculoskeletal conditions, particularly rheumatic diseases like RA and lupus, are among the most common causes of employment problems, according to Edward H. Yelin, PhD, who delivered Sunday’s ARP Distinguished Lecture.
-
FDA representatives provide updates on drug approvals, safety issues
The FDA has been busy during the COVID-19 pandemic, with emergency use authorizations for two rheumatology agents, approvals for new agents, and new indications and safety warnings for both prescription and OTC medications.